Skip to main content
. 2014 Oct 15;124(24):3561–3571. doi: 10.1182/blood-2014-07-587824

Figure 6.

Figure 6

IRAK-4 and MyD88 deficiencies impair IgD+IgM+CD27+ B-cell proliferation. (A) TLR agonists enrich IgM+IgD+CD27+ B cells in culture of control PBMCs, but not IRAK-4– or MyD88-deficient PBMCs. Gated on CD19+, CD27+. Representative of 4 experiments. (B) Quantification of total lymphocytes, IgM+IgD+ and IgM−IgD− CD27+ B cells with and without TLR stimulation. Data from 4 individuals per group. Box represents mean; whiskers represent standard error of mean. (C) Dilution of CFSE after TLR stimulation. Representative of 3 experiments. *P < .05.